Find trials
Search tips

Adding Pelvic CT with Calcium Scoring May Help Urologists Make Treatment Plans for Peyronie Disease

Overview

About this study

Adding a limited noncontrast pelvis CT with Agatston calcium scoring to evaluate and quantify calcified Peyronie plaques can increase the number of patients that qualify for collagenase Clostridium histolyticum (CCH) injection therapy compared with the qualitative assessment by penile duplex Doppler ultrasound (PDDU) and clinical exam.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult male over 18 years old.
  • Peyronie Disease with stable curvature considered for therapeutic intervention.
  • PDDU obtained at clinic visit.
  • Able to provide informed consent.

Exclusion Criteria: 

  • Implanted penile prosthesis or implanted urethral sphincter that would prevent adequate CT images.
  • Acute active Peyronie disease that would not be managed with injection or surgical therapy.

Eligibility last updated 5/2/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Lauren Alexander, M.D.

Closed for enrollment

Contact information:

Kendra Brown M.P.H., CCRP

Brown.Kendra@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20535973

Mayo Clinic Footer